secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0000950170-23-053875
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid sells 13% of soticlestat royalties & milestones to Ligand for $30M; cash runway into 2026
--------------------------------------------------------------------------------

- Ligand pays Ovid $30M (non-dilutive) for 13% of soticlestat regulatory/commercial milestones and tiered royalties (low double-digits to 20%).
- Ovid retains 87% of soticlestat economic interest; Takeda funds all development and has no further obligations for Ovid.
- Cash runway extended into 2026 (from into 2025), enabling expansion of pipeline of rare epilepsy and anti-seizure programs.
- Soticlestat is in two pivotal Phase 3 trials for Lennox-Gastaut and Dravet syndromes; Takeda anticipates regulatory filings in FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000095017023053875/0000950170-23-053875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000095017023053875/ovid-20231017.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-053875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer